PALB2 and neoplasm: We observed that both BARD1- and PALB2-mutant cases had significantly higher median HRD scores than WT tumors (p = 0.023 and p = 0.041, respectively), consistent with alterations in PALB2 or BARD1 conferring tumor HR deficiency.